NCT06644638View on ClinicalTrials.gov

Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis

CompletedOBSERVATIONAL
Enrollment

3,632

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

October 30, 2023

Study Completion Date

October 30, 2023

Conditions
Multiple Sclerosis
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT06644638 - Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple Sclerosis | Biotech Hunter | Biotech Hunter